Nonproportional hazards (NPH) have been observed in confirmatory clinical trials with time to event outcomes. Under NPH, the hazard ratio does not stay constant over time and the log rank test is no longer the most powerful test. The weighted log rank test (WLRT) has been introduced to deal with the presence of nonproportionality. We focus our attention on the WLRT and the complementary Cox model based on time varying treatment effect proposed by Lin and León. We investigate whether the proposed weighted hazard ratio (WHR) approach is unbiased in scenarios where the WLRT statistic is the most powerful test. In the diminishing treatment effect scenario where the WLRT statistic would be most optimal, the time varying treatment effect estimate...
Often in medical studies of time to an event, the treatment effect is not constant over time. In the...
The susceptibility of a clinical trial to allocation bias is related to the randomization procedure ...
The hazard ratio (HR) is the most common measure of treatment effect in clinical trials that use tim...
Non-proportional hazards have been observed in clinical trials. The log-rank test loses power and th...
1noProportional hazards are a common assumption when designing confirmatory clinical trials in onco...
Background: The logrank test and the Cox proportional hazards model are routinely applied in the des...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Abstract Background Non-proportional hazards are common with time-to-event data but the majority of ...
The hazard ratio derived from the Cox model is a commonly used summary statistic to quantify a treat...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
The hazard ratio (HR) has been the most popular measure to quantify the magnitude of treatment effec...
For survival data with nonproportional hazards, the weighted log-rank tests with a proper weighting ...
The proportional hazards (PH) assumption is the key assumption which may need to be examined in each...
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the ...
For both randomized clinical trials and prospective cohort studies, the Cox regression model is a po...
Often in medical studies of time to an event, the treatment effect is not constant over time. In the...
The susceptibility of a clinical trial to allocation bias is related to the randomization procedure ...
The hazard ratio (HR) is the most common measure of treatment effect in clinical trials that use tim...
Non-proportional hazards have been observed in clinical trials. The log-rank test loses power and th...
1noProportional hazards are a common assumption when designing confirmatory clinical trials in onco...
Background: The logrank test and the Cox proportional hazards model are routinely applied in the des...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Abstract Background Non-proportional hazards are common with time-to-event data but the majority of ...
The hazard ratio derived from the Cox model is a commonly used summary statistic to quantify a treat...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
The hazard ratio (HR) has been the most popular measure to quantify the magnitude of treatment effec...
For survival data with nonproportional hazards, the weighted log-rank tests with a proper weighting ...
The proportional hazards (PH) assumption is the key assumption which may need to be examined in each...
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the ...
For both randomized clinical trials and prospective cohort studies, the Cox regression model is a po...
Often in medical studies of time to an event, the treatment effect is not constant over time. In the...
The susceptibility of a clinical trial to allocation bias is related to the randomization procedure ...
The hazard ratio (HR) is the most common measure of treatment effect in clinical trials that use tim...